Sensus Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 8, 2019 and accepted by EDGAR at Nov 8, 2019, 11:01 ET.
Management's discussion and analysis
As filed, 15,888 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2018 (“Annual Report”). The statements in this discussion regarding our expectations of our future performance, liquidity and capital resources, our plans, estimates, beliefs and expectations that involve risks and uncertainties, and other non-historical statements in this discussion, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Please see the Introductory Note and Item 1A. Risk Factors of our Annual Report, as updated in our subsequent quarterly reports filed on Form 10-Q, and in our other filings made from time to time with the SEC after the date of this report.
Overview
We are a medical device company that is committed to providing highly effective, non-invasive and cost-effective treatments for both oncological and non-oncological skin conditions. We use a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is a result of over a decade of dedicated research and development. We have successfully incorporated SRT into our portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. In February 2019, we received FDA clearance of our Sculptura™, a robotic radiation oncology system that provides targeted intraoperative triple-modulated radiotherapy and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, with a single dose.
Components of our results of operations
We manage our business globally within one reportable segment, which is consistent with how our management reviews our business, prioritizes investment and resource allocation decisions and assesses operating performance.
Results of Operations
| For the Three Months Ended September 30, 2019 | 2018 | For the Nine Months Ended September 30, 2019 | 2018 | |
|---|---|---|---|---|
| Revenues | $5,840,945 | $6,333,996 | $18,753,839 | $18,346,193 |
| Cost of Sales | 1,997,111 | 2,165,345 | 6,654,835 | 6,296,653 |
| Gross Profit | 3,843,834 | 4,168,651 | 12,099,004 | 12,049,540 |
| Operating Expenses | ||||
| Selling and marketing | 2,124,146 | 1,971,539 | 6,649,754 | 6,146,759 |
| General and administrative | 957,184 | 907,746 | 2,933,985 | 3,163,621 |
| Research and development | 1,567,634 | 1,712,725 | 5,467,947 | 4,775,767 |
| Total Operating Expenses | 4,648,964 | 4,592,010 | 15,051,686 | 14,086,147 |
| Income (Loss) From Operations | (805,130) | (423,359) | (2,952,682) | (2,036,607) |
| Other Income (Expense) | ||||
| Interest income | 74,736 | 23,010 | 213,578 | 68,620 |
| Interest expense | — | (57,759) | — | (156,685) |
| Other Income (Expense), net | 74,736 | (34,749) | 213,578 | (88,065) |
| Net Loss | $(730,394) | $(458,108) | $(2,739,104) | $(2,124,672) |
Three months ended September 30, 2019 compared to the three months ended September 30, 2018
Revenue. Revenue was $5,840,945 for the three months ended September 30, 2019 compared to $6,333,996 for the three months ended September 30, 2018, a decrease of $493,051, or 7.8%. The decrease in revenue was primarily attributable to fewer units sold in the current quarter.
Cost of sales. Cost of sales was $1,997,111 for the three months ended September 30, 2019 compared to $2,165,345 for the three months ended September 30, 2018, a decrease of $168,234, or 7.8%. The decrease in cost of sales was due to a decrease in sales.
Gross profit. Gross profit was $3,843,834 for the three months ended September 30, 2019 compared to $4,168,651 for the three months ended September 30, 2018, a decrease of $324,817, or 7.8%. Our overall gross profit percentage was 65.8% in the three months ended September 30, 2019 as well as the corresponding period in 2018.
Selling and marketing. Selling and marketing expense was $2,124,146 for the three months ended September 30, 2019 compared to $1,971,539 for the three months ended September 30, 2018, an increase of $152,607, or 7.7%. The increase was primarily attributable to an increase in headcount and spending on marketing activities for SculpturaTM.
General and administrative. General and administrative expense was $957,184 for the three months ended September 30, 2019 compared to $907,746 for the three months ended September 30, 2018, an increase of $49,438, or 5.4%. The net increase in general and administrative expense was primarily due to professional services, partially offset by other decreases.
Research and development. Research and development expense was $1,567,634 for the three months ended September 30, 2019 compared to $1,712,725 for the three months ended September 30, 2018, an decrease of $145,091, or 8.5%. The decrease in research and development spending was primarily attributable to the SculpturaTM as production begins.
Other income (expense). We incur interest expense in connection with our secured credit facility with Silicon Valley Bank and interest income from our cash and investments. Interest expense decreased in 2019 with the decrease in borrowings on the line of credit. Interest income increased due to the increase of our investment in debt securities.
Nine months ended September 30, 2019 compared to the nine months ended September 30, 2018
Revenue. Revenue was $18,753,839 for the nine months ended September 30, 2019 compared to $18,346,193 for the nine months ended September 30, 2018, an increase of $407,646, or 2.2%. The growth in revenue was primarily attributable to an increase in the average selling price of our products.
Cost of sales. Cost of sales was $6,654,835 for the nine months ended September 30, 2019 compared to $6,296,653 for the nine months ended September 30, 2018, an increase of $358,182, or 5.7%. The increase in cost of sales was due to the increase in sales.
Gross profit. Gross profit was $12,099,004 for the nine months ended September 30, 2019 compared to $12,049,540 for the nine months ended September 30, 2018, an increase of $49,464, or 0.4%. Our overall gross profit percentage was 64.5% in the nine months ended September 30, 2019 compared to 65.7% in the corresponding period in 2018. The decrease in gross margin percentage was primarily due to changes in the mix of products sold.
Selling and marketing. Selling and marketing expense was $6,649,754 for the nine months ended September 30, 2019 compared to $6,146,759 for the nine months ended September 30, 2018, an increase of $502,995, or 8.2%. The increase was primarily attributable to the increase in headcount.
General and administrative. General and administrative expense was $2,933,985 for the nine months ended September 30, 2019 compared to $3,163,621 for the nine months ended September 30, 2018, a decrease of $229,636, or 7.3%. The net decrease was due primarily to a non-recurring stock compensation expense of $444,000 in the first quarter of 2018, partially offset by an increase in professional fees.
Research and development. Research and development expense was $5,467,947 for the nine months ended September 30, 2019 compared to $4,775,767 for the nine months ended September 30, 2018, an increase of $692,180, or 14.5%. The increase in research and development spending was primarily attributable to the FDA clearance of SculpturaTM as well as our ramp to production.
Other income (expense). We incur interest expense in connection with our secured credit facility with Silicon Valley Bank and interest income from our cash and investments. Interest expense decreased in 2019 with the decrease in borrowings on the line of credit. Interest income increased due to an increase in investment in debt securities.
Financial Condition
Our cash, cash equivalent and investment balance decreased to $14.9 million at September 30, 2019 from $15.4 million at December 31, 2018, primarily due to cash used in operating activities of $2.6 million offset by proceeds from exercised warrants for $2.7 million during the nine months ended in September 30, 2019.
There were no borrowings under the revolving line of credit at September 30, 2019 or December 31, 2018.
Liquidity and Capital Resources
Overview
Our liquidity position and capital requirements may be impacted by a number of factors, including the following:
- our ability to generate and increase revenue;
- fluctuations in gross margins, operating expenses and net results; and
- fluctuations in working capital.
Our primary short-term capital needs, which are subject to change, include expenditures related to:
- expansion of our sales, marketing and distribution activities; and
- expansion of our research and development activities.
We regularly evaluate our cash requirements for current operations, commitments, capital requirements and business development transactions, and we may elect to raise additional funds for these purposes in the future.
Cash flows
The following table provides a summary of our cash flows for the periods indicated:
(unaudited)
| Net Cash Provided by (Used In): | For the Nine Months Ended September 30, 2019 | 2018 |
|---|---|---|
| Operating Activities | $(2,566,572) | $(6,911,317) |
| Investing Activities | (5,632,621) | 342,260 |
| Financing Activities | 2,620,484 | 13,604,908 |
| Total | $(5,578,709) | $7,035,851 |
Cash flows from operating activities
Net cash used in operating activities was $2,566,572 for the nine months ended September 30, 2019, consisting of a net loss of $2,739,104 partially offset by an increase in net operating assets of $911,203 and by non-cash charges of $1,083,734. The increase in net operating assets was primarily due to an increase in inventory, accounts receivables and prepaids and other current assets, offset by a decrease in accounts payables and accrued expenses and warranties net of an increase in deferred revenue. Non-cash charges consisted of stock compensation expense, depreciation and amortizations and warranty provision. Net cash used in operating activities was $6,911,317 for the nine months ended September 30, 2018, primarily due to the operating loss and the increase in accounts receivable.
Cash flows from investing activities
Net cash used by investing activities was $5,632,621 mostly due to net investments in debt securities held-to-maturity for $5,090,137 during the nine months ended September 30, 2019. Net cash provided by investing activities was $342,260 for the nine months ended September 30, 2018 due to the maturity of debt securities held-to-maturity of $1,104,635, partially offset by $762,375 for acquisition of property and equipment.
Cash flows from financing activities
Net cash provided by financing activities was $2,620,484 during the nine months ended September 30, 2019 mostly from the exercise of 405,813 investor warrants. Net cash provided by financing activities was $13,604,908 during the nine months ended September 30, 2018, mainly from the net proceeds of $15,847,659 from offering of common stock offset by $2,214,970 repayment of our revolving credit facility.
Capital resources
On November 6, 2017, we filed a universal shelf registration statement to offer up to $20 million of our securities. In September 2018, we issued and sold 2,536,764 shares of our common stock in a follow-on public offering at a price of $6.80 per share, for aggregate offering proceeds of $17.25 million. We were previously limited in the amount of securities we were able to offer under a shelf registration statement pursuant to the SEC’s “baby shelf” rules. These rules previously restricted our issuance of securities under a shelf registration statement to one-third of our public float within a 12-month period. Because our public float exceeded $75 million within 60 days prior to the filing of our 2018 annual report on Form 10-K, we are not presently subject to this limitation with regard to our existing shelf registration statement. However, we must re-determine the applicability of the limitation at the time of filing another shelf registration statement and at the time of filing an annual report on Form 10-K (with respect to any shelf registration on file with the SEC at the time of filing). Depending on our public float in the future, we may again become subject to this limitation.
Indebtedness
Please see Note 4 to the financial statements.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and do not currently have, any off-balance sheet arrangements.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S., or GAAP. We have identified certain accounting policies as critical to understanding our financial condition and results of our operations. For a detailed discussion on the application of these and other accounting policies, see the notes to our financial statements and our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, for the year ended December 31, 2018.
JOBS Act
We qualify as an “emerging growth company” pursuant to the provisions of the JOBS Act. For as long as we are an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in Management’s Discussion and Analysis of Financial Condition and Results of Operations, exemptions from the requirements of holding advisory “say-on-pay” votes on executive compensation and shareholder advisory votes on golden parachute compensation. We have availed ourselves of the reduced reporting obligations in this Quarterly Report on Form 10-Q, and expect to continue to avail ourselves of the reduced reporting obligations available to emerging growth companies in future filings.
In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we plan to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.
Controls and procedures
As filed, 912 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Control and Procedures
As of September 30, 2019, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of September 30, 2019, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.
Changes in Internal Control over Financial Reporting
There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 1,058 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
An investment in our securities involves risks. You should carefully consider the risk factors as previously disclosed in our Form 10-K filed with the SEC for the year ended December 31, 2018, as updated in our subsequent quarterly reports, together with the other information in this Quarterly Report on Form 10-Q, including the financial statements and related notes, before deciding whether to purchase, hold, or sell our securities. The occurrence of any of these risks could harm our business, financial condition, or results of operations or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. There have been no material changes to the risk factors as previously disclosed in our Form 10-K filed with the SEC for the year ended December 31, 2018, the discussion of which is specifically incorporated by reference into this Quarterly Report on Form 10-Q.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $5.8m | us-gaap:Revenues |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $18.8m | us-gaap:Revenues |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $2.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $6.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-07-01 to 2019-09-30 | $3.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2019-01-01 to 2019-09-30 | $12.1m | us-gaap:GrossProfit |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $5.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$805.1k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$3.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$730.4k | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$2.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $542.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $6.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $32.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $35.8m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $6.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $9.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | $26.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-19-022496. Last ingested by Listed: Nov 14, 2026, 13:10 ET. Listed shows no prices and gives no investment advice.